NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

NCT06070961

Active Not RecruitingN/A

Sponsor: Fondazione Italiana Linfomi - ETS

Conditions: Follicular Lymphoma

Interventions: Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG

Countries: Italy

This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment undergoing frontline induction immuno-chemotherapy and anti-CD20 maintenance within the prospective FIL\_FOLL19 study (NCT05058404). Blood samples from patients will be collected before and at planned timepoints during treatment to evaluate humoral and cellular immunity against SARS-COV-2, VZV, tetanus and diphtheria and T-cell markers characterization.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Enrolment in FIL\_FOLL19 study
2. Previous vaccination for COVID-19 (at least 3 doses)
3. Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
4. Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
5. Signature of specific informed consent form

Exclusion Criteria:

None

Locations (14)

Avellino, AV, Italy
Alessandria, IT, Italy
Biella, IT, Italy
Milan, IT, Italy
Milan, IT, Italy
Novara, IT, Italy
Pavia, IT, Italy
Piacenza, IT, Italy
Torino, IT, Italy
Torino, IT, Italy
Ravenna, RA, Italy
Florence, Italy
Reggio Emilia, Italy
Siena, Italy